Archive: 1/02/2013

Ravicti approved for urea cycle disorders

(HealthDay)—Ravicti (glycerol phenylbutyrate) has been approved by the U.S. Food and Drug Administration to treat certain urea cycle disorders (UCDs) in people 2 years and older.

Caring friends can save the world

Craig Kielburger was only 12 years old when he travelled to India to see the plight of child laborers first hand. 14-year-old Malala Yousafzai took a stand against the Taliban with her campaign for women's education rights. ...

Propping open the door to the blood brain barrier

The treatment of central nervous system (CNS) diseases can be particularly challenging because many of the therapeutic agents such as recombinant proteins and gene medicines are not easily transported across the blood-brain ...

Autism speaks through gene expression

Autism spectrum disorders affect nearly 1 in 88 children, with symptoms ranging from mild personality traits to severe intellectual disability and seizures. Understanding the altered genetic pathways is critical for diagnosis ...

Type II diabetes and the Alzheimer's connection

A research team in Israel has devised a novel approach to identifying the molecular basis for designing a drug that might one day decrease the risk diabetes patients face of developing Alzheimer's disease. The team will present ...

page 1 from 7